Search Within

Department of Medicine

Formats
  1. Journal Article (19620)
  2. Meeting Abstract (16084)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22367)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10658)
  5. Survivorship Research (9352)
  6. Division of Subspecialty Medicine (7560)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1158)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39711)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
    Meeting Abstract

    Mohamadpour, M.; Sherman, E. J.; Kriplani, A.; Fetten, J. V.; Dunn, L.; Michel, L. S.; Hung, K. W.; Baxi, S. S.; McDonald, E.; Conybeare, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pathogenic germline variants in patients with endometrial cancer across diverse ancestries
    Meeting Abstract

    Liu, Y. L.; Gordhandas, S.; Arora, K.; Maio, A.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E. E.; Zhou, Q.; Iasonos, A.; Selenica, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
    Meeting Abstract

    Hanna, G. J.; Kaczmar, J. M.; Zandberg, D. P.; Wong, D. J. L.; Yilmaz, E.; Sherman, E. J.; Hernando-Calvo, A.; Sacco, A. G.; Chung, C. H.; Bohr, D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
    Meeting Abstract

    Chung, C. H.; Colevas, A. D. D.; Adkins, D.; Rodriguez, C. P.; Park, J. C.; Gibson, M. K.; Burtness, B.; Johnson, F. M.; Julian, R. A.; Saba, N. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Wong, W.; Cracchiolo, J. R.; Riaz, N.; Ganly, I.; Sherman, E. J.; Ho, A. L.; Morris, L.; Ghossein, R. A.; Haque, S.; Hung, K. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Banerjee, S. N.; Ring, K. L.; Van Nieuwenhuysen, E.; Fabbro, M.; Aghajanian, C.; Oaknin, A.; Colombo, N.; Santin, A.; Clamp, A. R.; Moore, K. N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Germline variants in non- BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival
    Meeting Abstract

    Kahn, R. M.; Selenica, P.; Boerner, T.; Xiao, Y.; Sia, T.; Sheehan, M.; Zhou, Q.; Iasonos, A.; Grisham, R. N.; O'Cearbhaill, R. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC)
    Meeting Abstract

    Halabi, S.; Guo, S. S.; Roy, A.; Rydzewska, L.; Godolphin, P.; Hussain, M. H. A.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)
    Meeting Abstract

    Aggarwal, R. R.; Dooley, K.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial
    Meeting Abstract

    McKay, R. R.; Xie, W.; Yang, X.; Rathkopf, D. E.; Laudone, V. P.; Bubley, G.; Einstein, D. J.; Chang, P.; Wagner, A.; Kane, C. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save